Inhibrx says Phase 2 trial shows INBRX-106 plus pembrolizumab lifts response rate to 48.3% in HNSCC

• Inhibrx reported primary endpoint results from a randomized Phase 2 HexAgon study of INBRX-106 with pembrolizumab in first-line HNSCC.
• The combination delivered a clearer treatment benefit than pembrolizumab alone, with deeper responses and longer disease control in the interim analysis.
• Benefits were strongest in HPV+ disease, supporting a sharper commercial and regulatory focus on that subgroup.
• The company plans a Phase 2 expansion of about 50 additional HPV+ OPSCC patients to support a potential accelerated approval pathway.
• A Phase 3 confirmatory trial is planned following FDA alignment on the expanded Phase 2 framework.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Inhibrx Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: 202609080730PR_NEWS_USPR_____LA42052) on September 08, 2026, and is solely responsible for the information contained therein.